GEP20247655B - Crystalline salt forms of kinase inhibitor - Google Patents
Crystalline salt forms of kinase inhibitorInfo
- Publication number
- GEP20247655B GEP20247655B GEAP201915849A GEAP2019015849A GEP20247655B GE P20247655 B GEP20247655 B GE P20247655B GE AP201915849 A GEAP201915849 A GE AP201915849A GE AP2019015849 A GEAP2019015849 A GE AP2019015849A GE P20247655 B GEP20247655 B GE P20247655B
- Authority
- GE
- Georgia
- Prior art keywords
- kinase inhibitor
- salt forms
- crystalline salt
- crystalline
- modulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856404P | 2019-06-03 | 2019-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20247655B true GEP20247655B (en) | 2024-08-26 |
Family
ID=69160360
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201915849A GEP20247655B (en) | 2019-06-03 | 2019-12-12 | Crystalline salt forms of kinase inhibitor |
| GEAP202415849A GEAP202415849A (en) | 2019-06-03 | 2019-12-12 | Crystalline salt forms of kinase inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202415849A GEAP202415849A (en) | 2019-06-03 | 2019-12-12 | Crystalline salt forms of kinase inhibitor |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230052703A1 (enExample) |
| EP (1) | EP3976587B1 (enExample) |
| JP (1) | JP7579281B2 (enExample) |
| KR (1) | KR102826380B1 (enExample) |
| CN (1) | CN113939503B (enExample) |
| AU (1) | AU2019449809B2 (enExample) |
| BR (1) | BR112021024300A2 (enExample) |
| CA (1) | CA3139148A1 (enExample) |
| CL (1) | CL2021003205A1 (enExample) |
| CO (1) | CO2021017343A2 (enExample) |
| CR (1) | CR20210616A (enExample) |
| DO (1) | DOP2021000236A (enExample) |
| ES (1) | ES3008963T3 (enExample) |
| GE (2) | GEP20247655B (enExample) |
| IL (1) | IL288484A (enExample) |
| MA (1) | MA56001A (enExample) |
| MX (1) | MX2021014773A (enExample) |
| PE (1) | PE20220962A1 (enExample) |
| PH (1) | PH12021553020A1 (enExample) |
| SG (1) | SG11202111978VA (enExample) |
| WO (1) | WO2020247019A1 (enExample) |
| ZA (1) | ZA202108034B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| KR102828472B1 (ko) * | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
| US20250368606A1 (en) | 2021-12-22 | 2025-12-04 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| ES2598530T3 (es) * | 2010-07-14 | 2017-01-27 | Betta Pharmaceuticals Co., Ltd. | Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| US20180009758A1 (en) * | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| MA48776A (fr) * | 2017-05-26 | 2020-04-08 | Exelixis Inc | Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation |
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| KR102828472B1 (ko) * | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2019
- 2019-12-12 MX MX2021014773A patent/MX2021014773A/es unknown
- 2019-12-12 EP EP19836340.0A patent/EP3976587B1/en active Active
- 2019-12-12 BR BR112021024300A patent/BR112021024300A2/pt unknown
- 2019-12-12 WO PCT/US2019/065980 patent/WO2020247019A1/en not_active Ceased
- 2019-12-12 US US17/616,124 patent/US20230052703A1/en active Pending
- 2019-12-12 GE GEAP201915849A patent/GEP20247655B/en unknown
- 2019-12-12 KR KR1020217041796A patent/KR102826380B1/ko active Active
- 2019-12-12 JP JP2021571744A patent/JP7579281B2/ja active Active
- 2019-12-12 PE PE2021002015A patent/PE20220962A1/es unknown
- 2019-12-12 CR CR20210616A patent/CR20210616A/es unknown
- 2019-12-12 PH PH1/2021/553020A patent/PH12021553020A1/en unknown
- 2019-12-12 ES ES19836340T patent/ES3008963T3/es active Active
- 2019-12-12 AU AU2019449809A patent/AU2019449809B2/en active Active
- 2019-12-12 GE GEAP202415849A patent/GEAP202415849A/en unknown
- 2019-12-12 CN CN201980097028.2A patent/CN113939503B/zh active Active
- 2019-12-12 SG SG11202111978VA patent/SG11202111978VA/en unknown
- 2019-12-12 CA CA3139148A patent/CA3139148A1/en active Pending
- 2019-12-12 MA MA056001A patent/MA56001A/fr unknown
-
2021
- 2021-10-20 ZA ZA2021/08034A patent/ZA202108034B/en unknown
- 2021-11-17 DO DO2021000236A patent/DOP2021000236A/es unknown
- 2021-11-28 IL IL288484A patent/IL288484A/en unknown
- 2021-12-02 CL CL2021003205A patent/CL2021003205A1/es unknown
- 2021-12-16 CO CONC2021/0017343A patent/CO2021017343A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553020A1 (en) | 2023-08-23 |
| JP7579281B2 (ja) | 2024-11-07 |
| ES3008963T3 (en) | 2025-03-25 |
| EP3976587A1 (en) | 2022-04-06 |
| EP3976587B1 (en) | 2024-12-04 |
| BR112021024300A2 (pt) | 2022-01-11 |
| AU2019449809B2 (en) | 2026-02-05 |
| SG11202111978VA (en) | 2021-11-29 |
| CN113939503A (zh) | 2022-01-14 |
| CN113939503B (zh) | 2024-05-07 |
| IL288484A (en) | 2022-01-01 |
| KR102826380B1 (ko) | 2025-06-26 |
| AU2019449809A1 (en) | 2021-12-16 |
| DOP2021000236A (es) | 2022-04-18 |
| CA3139148A1 (en) | 2020-12-10 |
| GEAP202415849A (en) | 2024-03-11 |
| KR20220016117A (ko) | 2022-02-08 |
| PE20220962A1 (es) | 2022-06-10 |
| US20230052703A1 (en) | 2023-02-16 |
| EP3976587C0 (en) | 2024-12-04 |
| JP2022535072A (ja) | 2022-08-04 |
| MA56001A (fr) | 2022-04-06 |
| WO2020247019A1 (en) | 2020-12-10 |
| CO2021017343A2 (es) | 2022-01-17 |
| ZA202108034B (en) | 2025-02-26 |
| CR20210616A (es) | 2022-03-22 |
| CL2021003205A1 (es) | 2022-09-30 |
| MX2021014773A (es) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20247655B (en) | Crystalline salt forms of kinase inhibitor | |
| PH12022551574A1 (en) | Egfr inhibitors | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| GEP20247596B (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| MX2020001832A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| EA201991884A3 (ru) | Ингибиторы g12c kras | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| EA201790779A1 (ru) | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений | |
| GEAP201914679A (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12021550857A1 (en) | Compounds, compositions, and methods for modulating cdk9 activity | |
| MX2024010863A (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cinasas dependientes de ciclina 2 (cdk2). | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
| MX2020013757A (es) | Inhibidor del fgfr, metodo de preparacion y aplicacion del mismo. | |
| ZA202205170B (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
| MX2020008273A (es) | Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos. | |
| MX2024009648A (es) | Formas cristalinas de sal de n-(4-(4-(ciclopropilmetil)piperazin-1 -carbonil)fenil)quinolin-8-sulfonamida. |